Increased fracture risk is commonly reported in cancer patients receiving radiotherapy, particularly at sites within the field of treatment. The direct and systemic effects of ionizing radiation on bone at a therapeutic dose are not well characterized in clinically relevant animal models. Using twentyweek male C57Bl/6 mice, effects of irradiation (right hindlimb; 2 Gy) on bone volume and microarchitecture were evaluated prospectively by microcomputed tomography and histomorphometry and compared to contralateral-shielded bone (left hindlimb) and non-irradiated control bone. One-week post-irradiation, trabecular bone volume declined in irradiated tibiae (−22%; p<0.0001) and femora (−14%; p=0.0586) and microarchitectural parameters were compromised. Trabecular bone volume declined in contralateral tibiae (−17%; p=0.003), and no loss was detected at the femur. Osteoclast number, apoptotic osteocyte number and marrow adiposity were increased in irradiated bone relative to contralateral and non-irradiated bone, while osteoblast number was unchanged. Despite no change in osteoblast number one-week postirradiation, dynamic bone formation indices revealed a reduction in mineralized bone surface and a concomitant increase in unmineralized osteoid surface area in irradiated bone relative to contralateral and non-irradiated control bone. Further, dose-and time-dependent calvarial culture and in vitro assays confirmed that calvarial osteoblasts and osteoblast-like MC3T3 cells were relatively radioresistant, while calvarial osteocyte and osteocyte-like MLO-Y4 cell apoptosis was 
Introduction
Irradiation at sites of malignancy in adjunct with surgery and/or chemotherapy has proven to be an effective anti-cancer strategy that reduces mortality rates. [1] As disease-free survival continues to improve with effective treatment approaches, long-term side effects of radiotherapy on the skeletal system have emerged. A typical treatment regimen of ionizing radiation for gynecological cancers consists of administration of up to 60 Gy fractionated over a six-week span. [2, 3] Healthy by-standing tissue, including bone, is estimated to absorb up to half of this dose (~30 Gy). [3, 4] Despite efforts to minimize dose-limiting side effects by protecting healthy tissues, the incidence of pathological fracture at sites in the direct path of therapeutic irradiation is reportedly increased relative to non-irradiated skeletal sites in cancer patients and survivors. [5] [6] [7] [8] [9] [10] [11] Patients receiving radiotherapy for pelvic tumors including cervical, rectal and anal cancers have increased risk of hip fracture relative to cancer patients who undergo surgery or chemotherapy alone. [6] [7] [8] [9] [10] [11] Likewise, a dosedependent relationship between radiation and rib fracture incidence has been identified in breast cancer patients. [5] In addition to evidence for direct effects of radiation therapy on bone, systemic reduction in bone density has been detected in cancer patients within the first year of radiotherapy, [7, 12, 13] and radiation-treated breast cancer patients are reported to have hip fracture rates up to 20 times higher than average reported fracture rates for breast cancer patients four years after diagnosis. [14] [15] [16] Taken together, these striking clinical findings implicate that both direct and systemic mechanisms are at play in the pathology of radiationinduced bone loss.
While the deleterious effects of ionizing radiation on bone are widely accepted, [3, 17] the direct and systemic mechanism(s) of radiation-induced bone loss at the cellular level are not well characterized, particularly in models which mimic a clinical setting of radiotherapy where exposure occurs at a localized site. Effects of radiation on bone typically have been characterized using total-body irradiation models where widespread systemic inflammation and radiation-induced hypogonadism can complicate data interpretation with regard to bone. Here we present results using a murine model of radiotherapy wherein the right hindlimb was selectively irradiated at a relatively low, clinically relevant dose of 2 Gy. Direct and indirect radiation-induced changes in bone volume and microarchitectural structures of bone were monitored prospectively for one week at irradiated bone sites and contralateralshielded bone sites, and compared to sham-irradiated age-matched non-irradiated controls.
Bone histology and histomorphometry
Hindlimbs were removed from mice at the time of experimental termination, fixed in 10% neutral-buffered formalin for 48h and stored in 70% ethanol. Tibiae were decalcified in 10% EDTA for two weeks, processed using an automated tissue processor (Excelsior, Thermoelectric), and embedded in paraffin. Mid-sagittal 3.5μm sections were stained with hematoxylin and eosin (H&E) with orange G and phloxine to visualize new bone, and with TRAP stain (tartrate-resistant acid phosphatase) to visualize osteoclasts. The number of osteoclasts (N.Oc/BS) and osteoblasts (N.Ob/BS) were identified and quantitated relative to the bone surface, and the total number of adipocytes distal to the growth plate in the proximal tibial metaphysis were quantified and expressed as adipocytes/mm 2 . Paraffin embedded sections were evaluated for apoptotic nuclei by detection of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), as per manufacturer's protocol (Klenow FragEL ™ Fragmentation Detection Kit; Calbiochem).
In order to assess dynamic bone parameters, undecalcified femora were dehydrated in graded alcohol (70-100%), cleared in xylene, and infiltrated and embedded with methyl methacrylate (MMA) under vacuum. Using an automated microtome (Microm HM 360, Thermo Scientific), 45μm transverse sections were removed from the femoral diaphysis at the midsection and mounted unstained on standard microscope slides. Bones were doublelabeled with calcein at the day of irradiation and at day six prior to the scheduled terminal necropsy at day seven to measure the following dynamic parameters: bone formation rate/ bone surface (BFR/BS; μm 3 /μm 2 /day), mineral apposition rate (MAR; μm/day) and mineralizing surface (MS/BS; %). In order to differentiate mineralized and osteoid bone tissue, sections were deplasticized, rehydrated, stained with von Kossa and counterstained with tetrachrome (MacNeal; Polysciences) for improved contrast. Non-mineralized osteoid bone tissue was assessed by measurement of the following parameters: osteoid volume (OV/ BS), osteoid surface (OS/BS) and osteoid width (μm). All sections were viewed on a Leica DM LB compound microscope outfitted with a Q-Imaging Micropublisher Cooled CCD color digital camera (Nuhsbaum Inc, McHenry, IL). Images were captured and analyzed using BioQuant Image Analysis Software version 12.1 (BIOQUANT Image Analysis Cooperation, Nashville, TN).
Calvarial bone culture assays
Calvariae were excised under sterile conditions from four-day-old Swiss White mice, cut in mid-sagitally, and incubated in 1mL of BGJ medium (Sigma) with 1% BSA, as previously described. [19] Calvarial bone cultures were irradiated on the same day of excision (0.244 Gy/ min; Faxitron X-ray; n=4/group) or treated with insulin as a positive control for bone formation (100μg/mL) and cultured up to ten days with media refreshment occurring every 72h. Bones were fixed, decalcified, paraffin-embedded, and sectioned. The total number of osteoblasts and new bone area (%) were quantified in blinded fashion on H&E stained sections, as previously described, [19] and apoptotic (TUNEL+) osteoblasts and osteocytes were quantitated and expressed as a percentage of the total for each respective cell type.
Flow cytometry
Murine calvarium-derived preosteoblastic MC3T3 cells (ATCC) and murine long bonederived osteocyte-like MLO-Y4 cells [20] were cultured in alpha-MEM with L-glutamin supplemented with antibiotics. Cells were seeded in 12-well plates (100,000 cells/well), grown to 80% confluence over a 48h period and irradiated with 2-20 Gy using 160kVp Xray at a dose rate of 2.44 Gy/min (Faxitron Bioptics, LLC Tucson, AZ) or treated with dexamethasone (Sigma) as a positive control for apoptosis. Washed and trypsinized cells were resuspended in 500μL of binding buffer containing 5μL of Annexin V-EGFP and 5μL of propidium iodide (PI; Biovision). Tubes were incubated at room temperature for 5m in the dark. Annexin-V-EGFP binding and PI staining were assessed by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences) and data were analyzed using Cell Quest software (BD Biosciences). The percentage of apoptotic cells was based on the evaluation of 10,000 events for each culture condition.
Osteoclastogenesis assays
Murine macrophage RAW264.7 cells (ATCC) were maintained in alpha-DMEM medium supplemented with antibiotics and 10% fetal bovine serum. Cells were seeded in 24-well plates (25,000/well) on a bone-mimetic surface (Corning OsteoSurface) in medium supplemented with deoxyribonucleosides, ribonucleosides, L-glutamine and RANKL (5-50ng/mL; R&D Systems) to stimulate osteoclastogenesis. In a parallel study, osteocyte-like MLO-Y4 or flushed bone marrow (BM) cells (125,000/well) were co-cultured with RAW264.7 cells under identical conditions. Briefly, BM cells were isolated under sterile conditions from the long bones of male C57Bl/6 mice and cultured on 90mm petri dishes for 2.5h at 37°C in alpha-DMEM and non-adherent BM cells were quantified and used for coculture studies. Wells were irradiated with 160kVp X-rays at a dose rate of 2.44 Gy/min using 2 Gy fractions applied consecutively on days one to four over the course of one week, cumulating doses of 2-8 Gy for each treatment condition. Medium was refreshed on day 4 and cells were fixed on day seven and stained for TRAP activity. Osteoclasts, defined as TRAP+ multinucleated (≥3) cells, were quantified for each condition (n=4 wells/group). Cells were cleared from the plate surface with 10% bleach, washed, dried and resorption pits were visualized on a Leica DM LB compound microscope outfitted with a Q-Imaging Micropublisher Cooled CCD color digital camera (Vashaw Scientific Inc.). Images were captured and analyzed using MetaMorph software (Universal Imaging Corporation).
Statistical analyses
Differences were determined by one-way ANOVA, with Bonferroni post hoc testing, or by paired or unpaired student t test, as appropriate (GraphPad, Prism 6, version 6.0c). Results are expressed as mean ± SEM and p<0.05 was considered significant.
Results

Skeletal and body composition changes following localized irradiation of the right hindlimb
Local and systemic effects of single site exposure to ionizing radiation were assessed by measurement of trabecular bone volume and microarchitecture at the proximal tibia and distal femur. Use of μCT allowed us to delineate a purely trabecular region of interest such that changes in bone volume and microarchitectural structure in highly metabolically active trabecular compartments could be detected with precision. [18] Irradiated hindlimbs and contralateral lead-shielded hindlimbs were compared to hindlimbs from age-matched nonirradiated control mice. Seven days post-irradiation (2 Gy), trabecular bone volume (BV/TV; %), was reduced by 22% at the tibia and by 14% at the femur relative to baseline measurements in irradiated limbs ( Fig. 1A-C ; Table 1 ). These changes in irradiated bone were significant relative to changes observed in non-irradiated control tibiae and femora (p<0.0001 and p<0.05, respectively) ( Fig. 1A-C) . Bone volume of contralateral tibiae in irradiated mice was reduced by 17% relative to baseline measurements seven days postirradiation ( Fig. 1A ,C; Table 1 ), and this decline was significant relative to changes in nonirradiated control bone volume at the tibia (p<0.001) (Fig. 1A,C) . Further, bone microarchitecture was altered in irradiated bone, evidenced by a 50% reduction in connectivity density, a 16% reduction in trabecular number and a 20% increase in trabecular spacing relative to baseline measurements at the proximal tibia ( Fig. 1D-F ; Table 1 ). This loss of connectivity density was significant (p<0.05) relative to changes observed in sham control tibiae (Fig. 1D) . At the femur, connectivity density and trabecular number were reduced by 45% and 13%, respectively, and spacing was increased by 16% relative to baseline measurements (Fig 1D-F ; Table 1) , with changes in trabecular number significantly reduced (p<0.01) relative to changes observed in sham control femora (Fig. 1E ). Similar trends were detected at the microarchitectural level at contralateral bone sites (Fig 1D-G ; Table 1 ); however, statistical significance was reached relative to changes observed in sham controls only in the case of reduced trabecular thickness (p<0.05) (Fig. 1G ). Cortical bone properties at the femoral midshaft assessed by μCT were not different between groups (data not shown).
One week after irradiation of the right hindlimb, body weight declined significantly (p<0.001) relative to non-irradiated sham control mice ( Fig. 2A) . No change was observed in lean mass percentage between groups (Fig. 2B) , as assessed by DXA, however, body fat mass declined significantly in irradiated animals one week after exposure (−22%; p<0.0001) (Fig. 2C) , and this change could explain the observed decline in body weight. Changes in BMD by DXA, a 2-dimensional integration of bone that includes both trabecular and cortical bone compartments, were not detected at the proximal tibia or distal femur (Fig.  2D ).
Cellular responses in bone to single site irradiation in vivo
Direct and systemic effects of focal irradiation in vivo were studied at the cellular level in bone tissue collected from irradiated and control mice. Quantitative histomorphometric analysis of TRAP+ osteoclasts revealed a statistically significant increase (p<0.05) in osteoclast number in irradiated bone relative to contralateral and control tibiae one week after irradiation (Fig. 3A,B) . No difference in osteoblast number was noted (Fig. 3C) . Detection of fragmented DNA (TUNEL+) in osteocytes, an early stage marker of cellular apoptosis, [21] was increased in the trabecular bone compartment of irradiated bone compared to non-irradiated controls (p<0.05) (Fig. 3D) . Quantitation of empty lacunae in trabecular bone, a late indicator of osteocyte death, revealed no significant differences between irradiated and non-irradiated bones in either trabecular or cortical bone compartments (Fig. 3E) .
Dynamic histomorphometric analyses were carried out in order to determine whether osteoblast activity was altered one week post-irradiation. Bone formation rate (BFR/BS; μm 3 /μm 2 /d) was reduced (p<0.05) in irradiated femora relative to controls (Fig. 4B) , and the mineralized surface relative to total bone surface (MS/BS) was likewise reduced in irradiated bone relative to both control (p<0.01) and contralateral femora (p<0.05) (Fig. 4D) . Osteoblast activity was also assessed by measurement of its cellular byproduct, osteoid, or unmineralized bone matrix. Interestingly, we found that osteoid volume (OV/BV) and osteoid surface (OS/BS) were increased (p<0.05) in irradiated femora (Fig. 4E,F) relative to controls, and that the mean osteoid width was thicker (p<0.05) in bone that had been irradiated, relative to contralateral bone (Fig. 4G ).
In alignment with previous reports of increased marrow adiposity following radiation therapy, [22] the adipocyte content of the marrow cavity of irradiated long bones was dramatically increased one week following exposure to 2 Gy (p<0.001) (Fig. 5A,B) , and this effect was restricted to irradiated bones, with no differences detected in contralateral limbs relative to sham-control bone (Fig. 5A,B) .
Differential response to irradiation by bone cells ex vivo
Next, we characterized the time-and dose-dependent effects of radiation on bone in vitro using a mouse calvarial bone formation assay. Consistent with results obtained from our in vivo studies, calvarial osteoblast number was not altered at any time point (1-10d) when irradiated at a dose of 2 Gy (Fig. 6A ). Recapitulating our findings in vivo, though at a slightly later time point (10d vs. 7d), irradiation of bone at 2 Gy induced a significant increase in new bone (p<0.01) in irradiated calvarial tissue relative to non-irradiated control tissues (Fig. 6B) . Exposure of bone to the higher dose of 10 Gy led to an eventual reduction in osteoblast number (p<0.001) relative to control tissues at the 10d time point, with no change in new bone formation at any time point (Fig. 6AB) . Detection of TUNEL+ apoptotic osteoblasts in the same calvarial assay was negligible for all groups (Fig. 6C) , however, similar to what was observed in vivo, osteocyte apoptosis was induced both doseand time-dependently in vitro (Fig. 6D,E) .
To further expand our understanding of the relative radiosensitivity of osteoblasts and osteocytes, we quantitated expression of Annexin V, a late stage marker of cellular apoptosis [23] using osteoblast-like MC3T3 cells and osteocyte-like MLO-Y4 cells. MC3T3 cell expression of Annexin V was significantly elevated at a dose of 10 Gy or higher 24h and 48h after radiation exposure (p<0.05 and p<0.001, respectively) (Fig. 7A,B) . Very similar results were observed in MLO-Y4 cell populations (Fig. 7C) , however, the dose-response study at 48h post-irradiation revealed elevated expression of Annexin V (p<0.05) in osteocyte-like cells after as little as 4 Gy, and expression of Annexin V increased concomitantly with increasing doses of radiation up to 20 Gy (Fig. 7D,E) .
Finally, effects of irradiation on osteoclastogenesis were evaluated using the murine macrophage osteoclast precursor cell line RAW264.7. Under minimal stimulation with the osteoclastogenic peptide RANKL (5ng/mL), direct irradiation of osteoclast precursor cells lead to a significant increase (p<0.01) in osteoclast number (Fig. 8A) and activity (Fig. 8B) , as assessed by measurement of resorption pit area on a bone-mimetic surface, relative to non-irradiated control wells. These effects, however, were observed only at a cumulative dose of 8 Gy. Interestingly, irradiation at 8 Gy of a co-cultured population of RAW264.7 with osteocyte-like MLO-Y4 cells or with flushed murine bone marrow (BM) cells increased osteoclast differentiation by nearly six fold relative to the osteoclast numbers in wells with irradiated RAW264.7 cells alone (p<0.05) (Fig. 8A) . Resorption area was increased in wells with an irradiated co-culture of RAW264.7 cells and BM cells relative to irradiated RAW264.7 cells alone (Fig. 8B ), but no relative difference was observed in resorption pit area in irradiated wells of RAW264.7 cells combined with MLO-Y4 cells.
Discussion
Radiation-induced bone loss has historically been attributed to a long-term impairment of bone formation resulting from reduced osteoblast cell proliferation and the depletion of the adult stem cell population from which bone-forming osteoblast cells are derived. [7, 13, [24] [25] [26] Our results are in agreement with recent studies that challenge the view that radiationinduced bone loss is primarily a late-stage event, [16, [27] [28] [29] as we present evidence for loss in trabecular bone volume and microstructure as early as one week post-irradiation. Furthermore, bone loss was detected in our model at sites of irradiation as well as at sites outside of the field of radiation, demonstrating that both local and systemic effects of irradiation have deleterious effects on the skeleton.
A rapid increase in osteoclastogenesis has been previously reported three days after totalbody exposure. [28, 29] Consistent with these reports, osteoclast number remained increased in trabecular bone one-week post-irradiation in our single-limb model. Interestingly, in vitro osteoclastogenesis assays presented here suggest that the direct effect of irradiation on osteoclast precursor cell differentiation is modest, but that irradiation of a co-culture of osteocyte-like cells or bone marrow cells with osteoclast precursors enhances osteoclastogenesis. These results indicate that signals from the osteocyte and/or bone marrow stroma may contribute to radiation-induced osteoclastic bone resorption. Using conditioned media collected from irradiated cells, we have yet to find evidence that soluble factors secreted from the osteocyte or bone marrow stroma are responsible for stimulation of osteoclastogenesis in this setting. Further studies will be required to identify possible signals within the bone microenvironment that contribute to osteoclast activation in the context of irradiation. The suppression of osteoclast activity using a bisphosphonate has previously been shown to abrogate radiation-induced bone loss in a preclinical model of total-body irradiation. [29] Collectively, preclinical data implicate a rapid and potentially sustained increase in osteoclastic bone resorption as one of the primary mechanisms of radiation-induced bone loss, supporting the use of adjuvant anti-resorptive therapy for cancer patients undergoing radiotherapy.
In addition to an upregulation of osteoclastic bone resorption in vivo, dynamic bone indices revealed a defect in the formation of mineralized bone at sites of direct irradiation, supporting the long-standing notion that ionizing radiation impairs bone formation. [7, 13, [24] [25] [26] 29] The timing however of these adverse effects on bone mineralization may occur sooner than previously thought, and moreover, impaired mineralization in our model was not driven by ablation of the osteoblast. To this point, the number of osteoblasts was not altered by 2 Gy exposure in vivo, consistent with our calvarial bone culture assays, which demonstrated that the proliferation of osteoblast cells was impaired only at higher doses (10 Gy) with no evidence of induction of apoptosis. Our in vivo and in vitro results consistently demonstrated that osteoblasts are relatively resistant to radiation-induced apoptosis. This is in full agreement with previous reports, which similarly demonstrate that osteoblast cells remain viable following exposure to doses between 10-30 Gy. [30, 31] Despite the impaired mineralization, a compensatory surge in osteoblast apposition of new osteoid was detected in our studies one-week post-irradiation, and this effect occurred concomitantly with the sustained increase in osteoclastogenesis, suggesting that radiation exposure at this dose did not compromise the coupling of resorption and formation mediated by bone's basic multicellular unit.
Little is known about the role of the osteocyte in radiation-induced bone loss, and the few studies that do account for osteocyte-related outcomes report mixed results. [3, 7, 25, 32] In our in vivo and in vitro models, doses of radiation as low as 2-4 Gy induced osteocyte apoptosis, providing evidence that the osteocyte may be highly sensitive to radiation exposure. Moreover, osteocytes appeared more radiosensitive than osteoblasts when compared headto-head in proliferation and apoptosis assays. Impaired osteocyte function and/or cell death following radiation exposure could blunt the mechanosensitivity of bone and its response to dynamic loads, slowing bone growth and retarding bone repair, thus compromising its material strength. Radiation-induced osteocyte apoptosis may be a previously unappreciated contributor to the etiology of long-term bone loss and increased risk of fracture in cancer patients.
A reciprocal relationship has been identified clinically between marrow adiposity and bone volume in cancer patients treated with radiotherapy. [6, 7, 33] Consistent with these clinical findings, we report a near threefold increase in marrow adiposity in conjunction with >20% reduction in bone volume in irradiated tibiae. Radiation-induced DNA damage to bone marrow mesenchymal stem cells (MSCs) from which bone-forming osteoblasts are derived has been linked to cellular senescence resulting in reduced osteogenic potential and increased adipogenic potential of MSCs. [22, 30, [33] [34] [35] [36] [37] [38] Despite no observed change in osteoblast number after one week, exhaustion of the MSC pool via an adipogenic lineage commitment switch could lead to a decrease in osteoblast number in our model at later time points, a postulate to be examined in future studies. While the underlying mechanisms responsible for fatty infiltration of the marrow following radiation exposure are still being clarified, it is clear that this marrow defect is strongly associated with bone loss and increased fracture risk, [6, 7, 33] and that damage to MSCs following radiotherapy could drive this defect in human cancer patients.
Many groups have reported weight loss in mice following total-body irradiation due to systemic toxicity and bone marrow suppression. [39] [40] [41] The mechanism of body weight decline and loss in fat mass following focal hindlimb irradiation, as observed in our study, is not known. Significant reduction in body weight in men [42] and women [43] has been associated with reduced bone mineral density (BMD) and increased fracture risk over time in clinical trials. Systemic changes in body weight and body composition in our mice could be a contributing factor to bone loss bilaterally at both contralateral and irradiated bone sites.
The single-limb irradiation model utilized here is advantageous in that direct and systemic effects of radiation on bone can be delineated. In agreement with clinical reports of systemic osteopenia in radiation-treated cancer patients, [7, 12, 13] significant bone loss was detected at sites outside the field of irradiation in our mice. These results lend credence to the clinicalapplicability of our model. Vascular damage, inflammation and the generation of reactive oxygen species (ROS) are thought to contribute to deleterious effects of radiation at distant skeletal and non-skeletal sites. [16, 44] Histomorphometric differences at contralateral bone sites relative to control bone sites did not reach significance at one-week post-irradiation. Cellular changes in bone in the contralateral limbs (e.g., increased osteoclast numbers) likely occurred at an earlier time point following irradiation (<7 days post-irradiation), and thus, our data at the one-week time point did not capture these relatively acute changes at contralateral sites. Pro-resorptive inflammatory cytokines including interleukin (IL)-1, IL-6, IL-17 and tumor necrosis factor (TNF)-α are known to be highly elevated within 24-48hrs following radiation exposure, [44] likely driving early bone loss following irradiation. [28, 29] Serum levels of IL-1, IL-6, IL-17 and TNF-α were assayed in our irradiated mice one-week post-irradiation, however, no differences were detected at this time point relative to control mice (data not shown), indicating that the period of increased inflammatory tone had likely subsided. Nevertheless, our finding of systemic bone loss following hindlimb radiation demonstrates that radiation-induced skeletal complications cannot be solely attributed to direct effects on bone, and the identification of the molecular mediator(s) of systemic bone loss could be important in developing bone-protective therapeutics for cancer patients.
While the prevention of pathological fractures in cancer patients is critical, other skeletal complications of radiation-induced bone loss may be important to consider. Multiple preclinical models have demonstrated that a heightened state of osteoclastic bone resorption can fuel the progression of cancer growth in bone. [45] [46] [47] Radiation-induced bone loss therefore could have serious implications with regard to cancer recurrence and skeletal metastasis in patients. During a state of heightened resorption, the bone microenvironment is rendered particularly favorable for cancer cell survival through the release of immobilized growth factors stored in the bone matrix (e.g., transforming growth factor-β, insulin-like growth factors, fibroblast growth factors, platelet-derived growth factor). [48] [49] Additionally, osteoclast-derived proteolytic enzymes such as cathepsin-K and matrix metalloproteinase-9 have been shown to promote angiogenesis, cancer cell invasiveness and engraftment at metastatic sites. [47, 49] Thus, it is critically important to monitor the skeletal health of cancer patients undergoing radiation treatment, or any anti-cancer therapeutic known to adversely affect bone (e.g., glucocorticoids, anti-estrogen therapy, GnRH agonists), as treatment-induced bone loss could increase the likelihood of cancer recurrence in bone. [50] Adjuvant treatment with an anti-resorptive therapy may be considered in an effort to prevent treatment-induced skeletal complications. Preclinical studies will be necessary to determine whether radiation-induced bone loss (direct or systemic) can influence the progression of cancer bone metastases.
In summary, the etiology of radiation-induced skeletal complications appears multifactorial. In our therapeutic model of single-limb irradiation, osteoclast activation, osteocyte apoptosis and increased marrow adiposity, which is associated with MSC senescence, appear to contribute to bone loss at sites of direct irradiation. Similar to what is reported clinically, systemic bone loss was detected in our model at distant sites, indicating that local perturbations to the bone microenvironment can have wide-sweeping systemic effects. The identification of mediators and mechanisms of both direct and systemic radiation-induced bone loss could be important for the development of therapies that prevent skeletally related events in cancer patients and survivors. Further studies will be necessary to assess the full time course of changes in bone at the microarchitectural and cellular levels, at both irradiated and non-irradiated bone sites. Taken together, these studies expand our current understanding of the radiosensitivity of bone tissue to the insult of ionizing radiation and emphasize the multi-dimensional and often complex nature of bone loss. Effects of in vivo radiation exposure (2 Gy) to the right hindlimb on (A) body weight, (B) total body lean mass, (C) total body fat mass and (D) bone mineral density (BMD) of the proximal tibia and distal femur in twenty-week male C57Bl/6 mice as assessed by dual energy X-ray absorptiometry (DXA). Data are expressed as mean percent change ±SEM relative to baseline measurements one week post-irradiation with differences determined by unpaired t test where ***p<0.001 and ****p<0.0001 (n=16/group). Time and dose-dependent effects of irradiation on cellular apoptosis of (A,B) osteoblast-like MC3T3 cells and (C-E) osteocyte-like MLO-Y4 cells in vitro, as assessed by flow cytometry. Results are presented as mean ±SEM with differences determined by one-way ANOVA with post-hoc testing where *p<0.05 and ***p<0.001 relative to 0 Gy. Table 1 Outcomes for Trabecular Bone Microarchitecture 
<0.0001
% change is expressed relative to baseline measurments prior to treatment. * P value is obtained from paired t-test with baseline measurements where n = 28 for control, n = 16 for contralateral and n = 16 for irradiated bones.
